BioStock: BrainCool comments on the cancer project in the US

With market approval and a breakthrough stamp in the US, BrainCool is approaching the commercial phase with Cooral System. CEO Martin Waleij tells BioStock that in parallel with possible fast track reimbursement processes, a clinical study will also be conducted in the U.S. to secure higher revenues in the long term. In addition, he sees opportunities for the studies, which the company is planning in collaboration with Medicare, to be financed through research grants. Alternatively that Medicare will provide compensation for patient recruitment in the study.

Read the full interview with Martin Waleij at biostock.se:

https://www.biostock.se/en/2023/05/braincool-comments-on-the-cancer-project-in-the-us/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/